Stockreport

[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STA...

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meeting Basel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RH [Read more]